Muscle Invasive Bladder Cancer Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corp

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Muscle Invasive Bladder Cancer pipeline constitutes 25+ key companies continuously working towards developing 30+ Muscle Invasive Bladder Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Muscle Invasive Bladder Cancer Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Muscle Invasive Bladder Cancer Market.

The Pipeline report for Non-Muscle Invasive Bladder Cancer provides a thorough evaluation of commercial and clinical aspects of pipeline products, spanning from pre-clinical development to market availability. It includes an extensive overview of each drug, detailing its mechanism of action, clinical studies, potential NDA approvals, and various product development activities. These encompass technology, collaborations, mergers, acquisitions, funding, designations, and other pertinent details related to the product’s development.

Some of the key takeaways from the Muscle Invasive Bladder Cancer Pipeline Report: 

Companies across the globe are diligently working toward developing novel Muscle Invasive Bladder Cancer treatment therapies with a considerable amount of success over the years.

Muscle Invasive Bladder Cancer companies working in the treatment market are Tollys, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, BristolMyers Squibb, Asieris Pharmaceuticals, and others, are developing therapies for the Muscle Invasive Bladder Cancer treatment

Emerging Muscle Invasive Bladder Cancer therapies in the different phases of clinical trials are- TL-532, AU-011, TARA-002, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, PF-06801591, Nivolumab, APL-1202, and others are expected to have a significant impact on the Muscle Invasive Bladder Cancer market in the coming years.

In May 2024, ANKTIVA® (nogapendekin alfa inbakicept), combined with bacillus Calmette-Guerin (BCG), represents a novel therapy for non-muscle invasive bladder cancer (NMIBC). It is approved for adult patients with BCG-unresponsive NMIBC, including carcinoma in situ (CIS), with or without papillary tumors. Developed by ImmunityBio, a US biotechnology company, ANKTIVA is the first-of-its-kind interleukin-15 (IL-15) receptor agonist designed to target BCG-unresponsive NMIBC. ANKTIVA activates the body’s natural killer and killer T-cell immune system to specifically attack tumor cells.

In February 2024, CG Oncology initiated the Phase III PIVOT-006 clinical trial for cretostimogene, targeting intermediate-risk non-muscle invasive bladder cancer (NMIBC), with the enrollment of the first subject receiving treatment. This open-label trial consists of two arms and is designed to include 426 NMIBC patients who have undergone transurethral resection of the bladder tumor (TURBT). In the initial phase of the PIVOT-006 trial, participants will receive a course of six weekly doses of adjuvant cretostimogene, each containing 1×10^12 viral particles per milliliter.

Muscle Invasive Bladder Cancer Overview

Muscle-invasive bladder cancer (MIBC) is a type of bladder cancer that has grown into or through the muscle layer of the bladder wall. This form of bladder cancer is more aggressive and has a higher risk of spreading to other parts of the body compared to non-muscle-invasive bladder cancer.

Get a Free Sample PDF Report to know more about Muscle Invasive Bladder Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/muscle-invasive-bladder-cancer-pipeline-insight

 

Emerging Muscle Invasive Bladder Cancer Drugs Under Different Phases of Clinical Development Include:

TL-532: Tollys

AU-011: Aura Biosciences

TARA-002: Protara Therapeutics

VAX 014: Vaxiion Therapeutics

Pemigatinib: Incyte Corporation

Erdafitinib: Janssen Pharmaceuticals

TLD 1433: Theralase Technologies

PF-06801591: Pfizer

Nivolumab: BristolMyers Squibb

APL-1202: Asieris Pharmaceuticals

Muscle Invasive Bladder Cancer Route of Administration

Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Muscle Invasive Bladder Cancer Molecule Type

Muscle Invasive Bladder Cancer Products have been categorized under various Molecule types, such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Muscle Invasive Bladder Cancer Pipeline Therapeutics Assessment

Muscle Invasive Bladder Cancer Assessment by Product Type

Muscle Invasive Bladder Cancer By Stage and Product Type

Muscle Invasive Bladder Cancer Assessment by Route of Administration

Muscle Invasive Bladder Cancer By Stage and Route of Administration

Muscle Invasive Bladder Cancer Assessment by Molecule Type

Muscle Invasive Bladder Cancer by Stage and Molecule Type

DelveInsight’s Muscle Invasive Bladder Cancer Report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I)

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Further Muscle Invasive Bladder Cancer product details are provided in the report. Download the Muscle Invasive Bladder Cancer pipeline report to learn more about the emerging Muscle Invasive Bladder Cancer therapies

 

Some of the key companies in the Muscle Invasive Bladder Cancer Therapeutics Market include:

Key companies developing therapies for Muscle Invasive Bladder Cancer are – Tollys, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, Bristol-Myers Squibb, Asieris Pharmaceuticals, UroGen Pharma, CG Oncology, Sesen Bio, Hamlet Pharma, AstraZeneca, Viralytics, ImmunityBio, Prokarium, Abraxis Bioscience, LIPAC Oncology, Rapamycin Holdings, Taizhou Hanzhong Biomedical, Spectrum Pharmaceuticals, FKD therapies, Altor Biosciences, Heat Biologics, EMD Sereno, QED Therapeutics, and others.

Muscle Invasive Bladder Cancer Pipeline Analysis:

The Muscle Invasive Bladder Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Muscle Invasive Bladder Cancer with aggregate therapies developed by each company for the same.

It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Muscle Invasive Bladder Cancer Treatment.

Muscle Invasive Bladder Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Muscle Invasive Bladder Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Muscle Invasive Bladder Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Muscle Invasive Bladder Cancer drugs and therapies

Muscle Invasive Bladder Cancer Pipeline Market Drivers

Increase in the number of patients suffering from non-muscle invasive bladder cancer. Approximately 70-75%bladder cancers are non-muscle invasive bladder cancer (NMIBC), development of novel therapies and favorable government policies are some of the important factors that are fueling the Muscle Invasive Bladder Cancer Market.

Muscle Invasive Bladder Cancer Pipeline Market Barriers

However, identifying the patient population with specific mutations for targeted therapy regimens, lack of awareness about the advanced cancer therapies and other factors are creating obstacles in the Muscle Invasive Bladder Cancer Market growth.

Scope of Muscle Invasive Bladder Cancer Pipeline Drug Insight    

Coverage: Global

Key Muscle Invasive Bladder Cancer Companies: Tollys, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, BristolMyers Squibb, Asieris Pharmaceuticals, and others

Key Muscle Invasive Bladder Cancer Therapies: TL-532, AU-011, TARA-002, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, PF-06801591, Nivolumab, APL-1202, and others

Muscle Invasive Bladder Cancer Therapeutic Assessment: Muscle Invasive Bladder Cancer current marketed and Muscle Invasive Bladder Cancer emerging therapies

Muscle Invasive Bladder Cancer Market Dynamics: Muscle Invasive Bladder Cancer market drivers and Muscle Invasive Bladder Cancer market barriers 

 

Request for Sample PDF Report for Muscle Invasive Bladder Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1. Muscle Invasive Bladder Cancer Report Introduction

2. Muscle Invasive Bladder Cancer Executive Summary

3. Muscle Invasive Bladder Cancer Overview

4. Muscle Invasive Bladder Cancer- Analytical Perspective In-depth Commercial Assessment

5. Muscle Invasive Bladder Cancer Pipeline Therapeutics

6. Muscle Invasive Bladder Cancer Late Stage Products (Phase II/III)

7. Muscle Invasive Bladder Cancer Mid Stage Products (Phase II)

8. Muscle Invasive Bladder Cancer Early Stage Products (Phase I)

9. Muscle Invasive Bladder Cancer Preclinical Stage Products

10. Muscle Invasive Bladder Cancer Therapeutics Assessment

11. Muscle Invasive Bladder Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Muscle Invasive Bladder Cancer Key Companies

14. Muscle Invasive Bladder Cancer Key Products

15. Muscle Invasive Bladder Cancer Unmet Needs

16 . Muscle Invasive Bladder Cancer Market Drivers and Barriers

17. Muscle Invasive Bladder Cancer Future Perspectives and Conclusion

18. Muscle Invasive Bladder Cancer Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

Stay up to date
Register now to get updates on promotions and coupons

Shopping cart

×